AstraZeneca announces discovery of a new class of antibiotic
Article Abstract:
AstraZeneca has announced the discovery of a new class of antibiotic agents with the potential to combat the escalating problem of drug-resistant bacteria. The compound belongs to an entirely novel structural class and lacks cross-resistance with current classes, thereby giving it a clear future role as resistance to current antibacterials continues to rise.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2007
User Contributions:
Comment about this article or add new information about this topic:
'Fast-track' drug approvals hit speed bumps in Japan
Article Abstract:
Iressa (gefitinib) a cancer drug is the fastest approved non-AIDS-related-drug by Japan. Families of patients who died after consuming Iressa filed a lawsuit against manufacturer AstraZeneca and the Japanese government.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2004
User Contributions:
Comment about this article or add new information about this topic:
Survey hints at uneven adoption of cancer vaccine
Article Abstract:
A survey that indicates an uneven adoption of the cancer vaccine Gardasil by people of different age-groups from different communities is discussed.
Publication Name: Nature Medicine
Subject: Health
ISSN: 1078-8956
Year: 2008
User Contributions:
Comment about this article or add new information about this topic:
- Abstracts: Intraobserver and interobserver variability of the amniotic fluid index. Intraobserver and interobserver variability for the histologic diagnosis of chorioamnionitis
- Abstracts: Aberrant crypt foci of the colon as precursors of adenoma and cancer. Taming transplantation with T cells
- Abstracts: Aneurysm treatments expand. Cocaine addiction therapy -- are we partially there? Cocaine's long run
- Abstracts: The interval between pregnancies and the outcome of subsequent births. Small-for-gestational-age infants and risk of fetal death in subsequent pregnancies
- Abstracts: Unstable angina pectoris. Time to treatment in primary percutaneous coronary intervention